北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学临床肿瘤学院  > 期刊论文
学科主题: 临床医学
题名:
Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)
作者: Zhou, Caicun; Wu, Yi Long; Liu, Xiaoqing; Wang, Changli; Chen, Gongyan; Feng, Ji Feng; Zhang, Shucai; Wang, Jie; Zhou, Songwen; Ren, Shengxiang; Lu, Shun; Zhang, Li; Hu, Cheng-ping; Luo, Yi; Chen, Lei; Ye, Ming; Huang, Jianan; Zhi, Xiuyi; Zhang, Yiping; Xiu, Qingyu
刊名: JOURNAL OF CLINICAL ONCOLOGY
发表日期: 2012-05-20
卷: suppl.S, 期:15
收录类别: SCI ; ISTP
文章类型: Meeting Abstract
WOS标题词: Science & Technology
类目[WOS]: Oncology
研究领域[WOS]: Oncology
语种: 英语
WOS记录号: WOS:000318009804317
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/66429
Appears in Collections:北京大学临床肿瘤学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Jiangsu Prov Canc Hosp, Nanjing, Jiangsu, Peoples R China
2.Peking Univ, Canc Hosp, Beijing 100871, Peoples R China
3.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
4.Harbin Med Univ, Affiliated Hosp 3, Harbin, Peoples R China
5.Tongji Univ, Sch Med, Shanghai Pulm Hosp, Shanghai 200092, Peoples R China
6.Acad Mil Med Sci, Ctr Canc, Hosp 307, Beijing, Peoples R China
7.Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
8.Capital Med Univ, Bejiing Chest Hosp, Beijing, Peoples R China
9.Jiao Tong Univ, Shanghai Chest Hosp, Shanghai 200030, Peoples R China
10.Sun Yat Sen Univ, Ctr Canc, Guangzhou 510275, Guangdong, Peoples R China
11.Shanghai Jiao Tong Univ, Renjin Hosp, Shanghai 200030, Peoples R China
12.Capital Med Univ, Beijing Lung Canc Ctr, Beijing, Peoples R China
13.Second Mil Med Univ, Changzheng Hosp, Shanghai, Peoples R China
14.Cent S Univ, Xiang Ya Hosp, Changsha, Hunan, Peoples R China
15.Hunan Prov Tumor Hosp, Changsha, Hunan, Peoples R China
16.Shantou Univ, Coll Med, Canc Hosp, Shantou, Peoples R China
17.Soochow Univ, Affiliated Hosp 1, Suzhou, Peoples R China
18.Zhejiang Canc Hosp, Hangzhou, Zhejiang, Peoples R China

Recommended Citation:
Zhou, Caicun,Wu, Yi Long,Liu, Xiaoqing,et al. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) versus carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC)[J]. JOURNAL OF CLINICAL ONCOLOGY,2012,suppl.S(15).
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Zhou, Caicun]'s Articles
[Wu, Yi Long]'s Articles
[Liu, Xiaoqing]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Zhou, Caicun]‘s Articles
[Wu, Yi Long]‘s Articles
[Liu, Xiaoqing]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
所有评论 (0)
暂无评论
 
评注功能仅针对注册用户开放,请您登录
您对该条目有什么异议,请填写以下表单,管理员会尽快联系您。
内 容:
Email:  *
单位:
验证码:   刷新
您在IR的使用过程中有什么好的想法或者建议可以反馈给我们。
标 题:
 *
内 容:
Email:  *
验证码:   刷新

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace